

Piramal Pharma Solutions partners with IntoCell, expanding Payload-Linker Platform and Bioconjugate Capabilities

30 October 2025 | News

Agreement supports ADCelerate™, Piramal's rapid approach to ADC development and manufacture



Mumbai-based Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO), has signed a Memorandum of Understanding (MoU) to solidify its strategic partnership and explore potential collaboration opportunities in ADC development with IntoCell Inc., a leading Korean biotechnology company specialising in innovative antibody-drug conjugate (ADC) linker and payload platform technologies.

Pursuant to this non-exclusive and non-binding agreement, IntoCell will explore licensing opportunities for its proprietary drug-linker technologies with Piramal's clients. In exchange, Piramal will offer comprehensive contract research, development, and manufacturing of bioconjugates, including ADCs, to IntoCell and its client base.

This partnership enhances Piramal's robust, existing payload-linker and bioconjugation capabilities. Through this agreement, Piramal can now offer clients a broader range of payload-linkers, and faster bioconjugate development times, thereby improving its service offerings and competitiveness in this specialised field. The licensing agreement centers on IntoCell's proprietary drug-linker technologies, including its OHPAS linker, Duocarmycin based OHPAS-payload, Nexatecan based OHPAS-payload, and iso-Nexatecan based GGFG-payload.

Additionally, this agreement strengthens ADCELERATE™, Piramal's rapid, integrated approach to bioconjugate development and manufacture. Utilising IntoCell's existing resources allows Piramal to further streamline the path from concept to clinic.